Interleukin 35 Protein (IL35) (AA 23-215, AA 23-228) (Fc Tag)
-
- Antigène Voir toutes Interleukin 35 (IL35) Protéines
- Interleukin 35 (IL35)
- Type de proteíne
- Recombinant
- Attributs du protein
- AA 23-215, AA 23-228
-
Origine
- Souris
-
Source
- CHO Cells
- Purification/Conjugué
- Cette Interleukin 35 protéine est marqué à la Fc Tag.
- Fonction
- IL-35 (mouse):Fc (human) (rec.)
- Specificité
- A soluble dimeric fusion protein consisting of the extracellular domain of mouse IL12a subunit (aa 23-215) is fused to the Fc region of human IgG1, and the mouse Ebi3 subunit (aa 23-228) linked to IL12a by disulfide bonds.
- Attributs du produit
- Protein. A soluble dimeric fusion protein consisting of the extracellular domain of mouse IL12a subunit (aa 23-215) is fused to the Fc region of human IgG1, and the mouse Ebi3 subunit (aa 23-228) linked to IL12a by disulfide bonds. Source: CHO cells. Endotoxin content: <0.06EU/μg protein (LAL test, Lonza). Lyophilized from 0.2μm-filtered solution in PBS. Purity: >98 % (SDS-PAGE). Interleukin-35 (IL-35) is a novel IL-12 family cytokine produced by regulatory T cells (Treg) but not by resting or activated effector T cells (Teff). IL-35 is a heterodimeric protein composed of EBI3 (Epstein-Barr-Virus-induced gene 3) and IL-12a (p35). EBI3 is a downstream target of Foxp3, a transcription factor required for Treg-cell development and function, and thus Treg-cell restriction of IL35 occurs. Regulatory T cells are essential for maintaining self tolerance and preventing autoimmunity, and IL-35 is identified as a molecule that mediates the immune suppression function of Treg-cell. As an inhibitory cytokine, IL-35 induces proliferation of Treg-cell populations but suppresses Th17 cell development. Studies in mice show the absence of either IL-35 chain from Treg-cell reduces the cells' ability to suppress inflammation using an experimental model for inflammatory bowel disease. IL-35 is suggested as a potential target of immunotherapy. Recently, insufficient IL-35 levels were shown to play a pivotal role in the development of type 1 diabetes (T1D) and autoimmune diseases.
- Pureté
- >98 % (SDS-PAGE)
- niveau d'endotoxine
- <0.06EU/μg protein (LAL test, Lonza).
- Biological Activity Comment
- Bioactivity was measured in a cell proliferation assay of Con A activated mouse splenocytes.
- Top Product
- Discover our top product IL35 Protéine
-
-
- Restrictions
- For Research Use only
-
- Format
- Lyophilized
- Concentration
- Lot specific
- Buffer
- Lyophilized from 0.2μm-filtered solution in PBS.
- Conseil sur la manipulation
- Avoid freeze/thaw cycles.
- Stock
- 4 °C,-20 °C
- Stockage commentaire
-
Short Term Storage: +4°C
Long Term Storage: -20°C
Use & Stability: Stable for at least 1 year after receipt when stored at -20°C. Working aliquots are stable for up to 3 months when stored at -20°C.
-
- Antigène
- Interleukin 35 (IL35)
- Autre désignation
- IL-35 (IL35 Produits)
- Sujet
-
Alternate Names/Synonyms: Interleukin-35
Product Description: Interleukin-35 (IL-35) is a novel IL-12 family cytokine produced by regulatory T cells (Treg) but not by resting or activated effector T cells (Teff). IL-35 is a heterodimeric protein composed of EBI3 (Epstein-Barr-Virus-induced gene 3) and IL-12a (p35). EBI3 is a downstream target of Foxp3, a transcription factor required for Treg-cell development and function, and thus Treg-cell restriction of IL35 occurs. Regulatory T cells are essential for maintaining self tolerance and preventing autoimmunity, and IL-35 is identified as a molecule that mediates the immune suppression function of Treg-cell. As an inhibitory cytokine, IL-35 induces proliferation of Treg-cell populations but suppresses Th17 cell development. Studies in mice show the absence of either IL-35 chain from Treg-cell reduces the cells' ability to suppress inflammation using an experimental model for inflammatory bowel disease. IL-35 is suggested as a potential target of immunotherapy. Recently, insufficient IL-35 levels were shown to play a pivotal role in the development of type 1 diabetes (T1D) and autoimmune diseases.
- NCBI Accession
- NP_032377
-